428 related articles for article (PubMed ID: 18347186)
21. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
22. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
24. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
25. Geldanamycin, a HSP90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro.
Wu WC; Kao YH; Hu PS; Chen JH
Exp Eye Res; 2007 Nov; 85(5):721-31. PubMed ID: 17870069
[TBL] [Abstract][Full Text] [Related]
26. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
27. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
Williams CR; Tabios R; Linehan WM; Neckers L
J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
[TBL] [Abstract][Full Text] [Related]
28. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
Hanson BE; Vesole DH
Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
[TBL] [Abstract][Full Text] [Related]
29. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
30. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
[TBL] [Abstract][Full Text] [Related]
31. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
[TBL] [Abstract][Full Text] [Related]
32. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells.
Xiao H; Li S; Zhang D; Liu T; Yu M; Wang F
Oncol Rep; 2013 Jan; 29(1):329-34. PubMed ID: 23076497
[TBL] [Abstract][Full Text] [Related]
33. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
35. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.
Yu W; Wang J; Jin J; Qian W; Qian J; Cheng Y; Wang L
Leuk Res; 2011 Sep; 35(9):1212-8. PubMed ID: 21632108
[TBL] [Abstract][Full Text] [Related]
37. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
[TBL] [Abstract][Full Text] [Related]
38. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
39. Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin.
Bae Y; Buresh RA; Williamson TP; Chen TH; Furgeson DY
J Control Release; 2007 Sep; 122(1):16-23. PubMed ID: 17651857
[TBL] [Abstract][Full Text] [Related]
40. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]